Transport of Full-Length Proteins through a Nanopore: One Step Closer to Single-Molecule Proteomics
Clinical Chemistry · 2024
DOI: 10.1093/clinchem/hvad201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2024. Verfasst von Priscilla S W Yeung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University, Stanford, CA, United States. Hauptthemen laut MEDLINE: Nanopores. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 2 Literaturangaben.
Abstract (Originalsprache)
Proteins are a major group of clinical diagnostic markers. Many clinical testing methods for proteins are primarily based on superficial molecular features of proteins such as specific reactivity for enzymatic assays or epitope binding for immunoassays. Besides quantifying proteins, these technologies provide little information about primary structural characteristics. Alternatively, mass spectrometry (MS) can elucidate the structures of proteins, but current MS-based proteomic methods are often limited by sensitivity and the need for reference sequence matching. Furthermore, the test results from all these technologies represent ensemble averages of numerous molecules measured at once, which may not accurately reflect the possible heterogeneity of proteoforms. The ultimate goal of protein measurement would be the ability to observe the complete primary structure of every single protein molecule along with its posttranslational modifications (PTMs). Recent advancements in nanopore sequencing technologies have made a groundbreaking step towards this goal. Protein sequencing through a nanopore requires a denatured protein strand to pass the narrow pore in a predictable orientation one amino acid at a time. The sequential conduction of individual residues is associated with signature changes in the electrical current across the pore, which can then be used to derive the complete amino acid sequence as well as PTMs of a single protein molecule. An article by Yu et al. showcases a novel enzyme-free approach to thread an intact protein through a nanopore (1). Prior to this study, the development of nanopore protein sequencing often followed the footsteps of DNA nanopore sequencing, with several research groups using the enzymes unfoldase and translocase as surrogates for DNA helicase to denature and guide protein molecules through the pore. Yu et al. showed that a high-concentration guanidium chloride (GdmCl) buffer could both denature the protein and create a sufficiently strong electro-osmotic force to drive it through an α-hemolysin nanopore (1). The unidirectional transport was facilitated by the coating of Gdm+ ions near the mouth of the nanopore, which generated a local net positive charge to facilitate protein capture. The transport efficiency was greatly enhanced by tagging a negatively charged polyaspartate tail or DNA oligomer. As a proof of concept, they demonstrated successful denaturation and single-molecule fingerprinting of α-helix–rich maltose-binding protein and stable β-barrel–structured green fluorescent protein. Notably, a supervised machine learning model was implemented to differentiate mixtures of tagged forms of these two proteins with over 90% accuracy. This innovative technique opens new avenues for enzyme-free nanopore protein sequencing. Another report by Martin-Baniandres et al. showed that GdmCl-based electro-osmotic flow through an engineered α-hemolysin nanopore could differentiate PTMs on a protein (2). A substantial amount of progress is still needed to mature the nanopore protein sequencing technology. However, with the rapid ascent of artificial intelligence algorithms, we anticipate that it will not be long until individual amino acids and PTMs within an intact protein can be determined reliably. We foresee that the power of de novo protein sequencing and digital quantitation provided by nanopore protein sequencing will revolutionize the landscape of proteomics and clinical testing of protein markers. The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Priscilla Yeung (Conceptualization-Equal, Investigation-Lead, Writing—original draft-Lead, Writing—review & editing-Supporting), and Ruben Luo (Conceptualization-Equal, Investigation-Supporting, Writing—original draft-Supporting, Writing—review & editing-Lead) No authors declared any potential conflicts of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University, Stanford, CA, United States.
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, United States.
Zitieren
APA
Yeung, P. S. W., & Luo, R. Y. (2024). Transport of Full-Length Proteins through a Nanopore: One Step Closer to Single-Molecule Proteomics. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvad201
Vancouver
Yeung PSW, Luo RY. Transport of Full-Length Proteins through a Nanopore: One Step Closer to Single-Molecule Proteomics. Clinical Chemistry. 2024. doi:10.1093/clinchem/hvad201
BibTeX
@article{Yeung2024,
author = {Yeung, Priscilla S W and Luo, Ruben Yiqi},
title = {Transport of Full-Length Proteins through a Nanopore: One Step Closer to Single-Molecule Proteomics},
journal = {Clinical Chemistry},
year = {2024},
doi = {10.1093/clinchem/hvad201}
}
EUVIMED